Upregulation of the immune response may be involved in the pathogenesis of schizophrenia with changes occurring in both peripheral blood and brain tissue. To date, microarray technology has provided a limited view of specific inflammatory transcripts in brain perhaps due to sensitivity issues. Here we used SOLiD Next Generation Sequencing to quantify neuroimmune mRNA expression levels in the dorsolateral prefrontal cortex of 20 individuals with schizophrenia and their matched controls. We detected 798 differentially regulated transcripts present in people with schizophrenia compared with controls. Ingenuity pathway analysis identified the inflammatory response as a key change. Using quantitative real-time PCR we confirmed the changes in candidate cytokines and immune modulators, including interleukin (IL)-6, IL-8, IL-1b and SERPINA3. The density of major histocompatibility complex-II-positive cells morphologically resembling microglia was significantly increased in schizophrenia and correlated with IL-1b expression. A group of individuals, most of whom had schizophrenia, were found to have increased inflammatory mRNA expression. In summary, we have demonstrated changes in an inflammatory response pathway that are present in B40% of people diagnosed with schizophrenia. This suggests that therapies aimed at immune system attenuation in schizophrenia may be of direct benefit in the brain.
INTRODUCTION
Schizophrenia is a severe neuropsychiatric disorder affecting around 1% of the world's population. Current treatments are ineffective at addressing the full spectrum of symptoms. Understanding schizophrenia's causes will allow us to better tailor the treatments to specific biological subgroups, which may be present under the broad diagnostic group of schizophrenia. Previous studies have used microarrays to examine the brain transcriptome of individuals with schizophrenia to establish patterns of gene expression changes implicating GABAergic, synaptic and myelin pathways, as well as inflammatory/immune response. 1--6 However, microarray studies have been limited by target specificity, restricted linear range and background interference. 7, 8 Nextgeneration sequencing (NGS), specifically RNA-Seq, overcomes these problems through the use of massively parallel nucleotide sequencing of small sections of the transcriptome and digital reassembly of the reads, resulting in no upper limit to quantification and a very sensitive detection threshold. 7 The immune system's role in schizophrenia is somewhat controversial but evidence from genomic, blood, postmortem and in vivo imaging studies are leading toward a greater consensus that immune activation is involved.
9--12 A significant positive genetic association between schizophrenia and the human leukocyte antigen (HLA) locus responsible for major histocompatibility complex (MHC) expression and the genetic region containing cytokines interleukin (IL)-1a, IL-1b and IL1RA have been found. 13--15 Serum cytokines are also significantly increased in schizophrenia (IL-6, IL-8). 10,16--21 Elevations in expression of other immune-related genes, but not cytokines, have been found in the dorsolateral prefrontal cortex (DLPFC) of individuals with schizophrenia. 1, 5 In brain, cytokines are synthesized and secreted by the resident immune cells and microglia, among others. Microglia have diverse functions including serving as antigen-presenting cells through the MHC-II receptor. 22--24 Brain microglia have been measured using in vivo positron emission tomography and in vitro binding with significant increases in ( 11 C)PK-11195 binding observed in people with schizophrenia compared with controls in two out of three studies. 25--27 This evidence would indicate that there is a subset of living individuals with schizophrenia who may have increased immune responses in their brain. Thus, we hypothesized that we would detect increased microglia density and increased mRNA levels of pro-inflammatory cytokines in the brains of people with schizophrenia.
The current study is among the first to use NGS to examine the transcriptome of DLPFC from 20 individuals with schizophrenia and 20 matched controls, providing the most sensitive examination of gene expression changes in schizophrenia available to date. In addition, the RNA-Seq results were confirmed by quantitative PCR (qPCR) in an expanded cohort (n ¼ 74) in which microglial density was also measured through immunohistochemistry, cell counting, and western blotting. 28 This human study was carried out in accordance with the latest version of the Declaration of Helsinki after review by the Human Research Ethics Committee at the University of New South Wales (HREC #07261). Samples for sequencing were chosen to reduce subject variability by being male and having a primary diagnosis of schizophrenia (excluding schizoaffective). The tissue from control (n ¼ 20) and schizophrenia (n ¼ 20) groups remained; age, pH, PMI, RIN and duration of time in freezer matched to controls.
MATERIALS AND METHODS

NGS library preparation and sequencing
Twelve micrograms of RNA from each of the 40 samples was used in creation of the library for sequencing. Briefly the RNA was DNase treated using TURBO DNA-free (Ambion, Austin TX, USA) before the depletion of ribosomal RNA using the Ribominus kit (Invitrogen, Carlsbad, CA, USA). The resulting RNA was fragmented and the SOLiD library prepared using the Total RNA-Seq kit (Invitrogen). Quality control of the library was assessed by size (480% and within 200--300 bp) using a bioanalyser. Samples were run with four individuals per slide on the SOLiDv4 (Life Technologies, Carlsbad, CA, USA). Reads were unpaired and 50 nt in length. Average reads per individual were 135 355 990 (±32 081 820) and did not differ between diagnostic groups.
Mapping
RNA-Seq reads were aligned to the genome using the X-MATE recursive mapping pipeline 29 and the following parameters: (i) strandspecific mapping, where tags are expected to align on the sense strand; (ii) raw tag length of 50 nucleotides; (iii) genome and junction mapping performed with the ISAS mapping engine; 30 (iv) recursive mapping N, M where N ¼ length of tag and M ¼ number of allowable mismatches was 50, 5 then 45, 5 then 40, 5 then 35, 3; (v) tags aligning to multiple genomic locations were discarded; (vi) exhaustive alignments were enabled; (vii) quality filtering was disabled; and (viii) mapping to junctions was enabled. During the alignment to junctions, 10 nucleotides were required to overlap the exon--exon boundary for tag lengths X40 nt, and five nucleotides were required to overlap for tag lengths o40 nt. Exon--exon junction libraries were constructed using Ref-Seq hg19 (April 2011) annotations using the scripts distributed with X-MATE. Average reads mapped per individual were 59 418 524 (±20 208 906) or 43% (min: 11% max: 52%) of total.
NGS analysis
Mapping results were converted into an interval format for processing using Galaxy (main.g2.bx.psu.edu). Intervals were joined to the exon-annotated genome (hg19) and counts per exon were calculated before exporting into R. The counts were aggregated into 33 105 transcripts and analyzed using EdgeR (www.bioconductor.org/packages/2.3/bioc/html/edgeR.html) to calculate differential gene expression between individuals with schizophrenia and controls. Unexpected expression of female-linked sex genes (as shown in Weickert et al.
31
) was found in one phenotypically male individual (putative XXY), who was excluded from further analysis. Information on fold change and multiple correction-adjusted P-values according to diagnostic class was imported into Ingenuity Pathway Analysis (Ingenuity Systems, www.ingenuity.com) for pathway analysis. The gene list was filtered preserving only those with a false discovery rate o0.05. Remaining significant genes were examined with reference to Ingenuity's pathway analysis based on curated literature findings for directly experimentally observed results for human. The top biological function was examined and a gene list created. A relational network was calculated from these genes and the top seven candidates were confirmed using qPCR.
Quantitative PCR Preparation of complementary DNA and qPCR experiments were performed as described previously on the entire cohort of 74 individuals. 28 The following probes were used for the inflammatory genes: SERPINA3 (Hs003153674_m1), IL6 (Hs00174131_m1), IL6ST (Hs01006741_m1), IL8 (HS00174103_m1), IL1B (Hs01555410_m1), NFKB1 (Hs00765730_m1), PTGS2 (Hs00153133_m1), with ACTB (Hs99999903_m1), GAPDH (Hs99999905_m1), TBP (Hs00427621_m1) and UBC (Hs00824723_m1) used as normalizing genes. Cycling conditions and reaction amounts were as previously described. 28 Some measurements, particularly SERPINA3 and IL8, had qPCR wells, which did not amplify (average: n ¼ 1.64, range: 0--6 wells per measurement per group).
Western blotting
To measure HLA-DA/DR/DQ protein expression, western blotting was performed as previously described. 32 Briefly, 40 mg of frozen tissue from the DLPFC was homogenized in 400 ml of homogenization buffer. Protein (20 mg) was diluted in Laemmli buffer, and separated by SDS-polyacrylamide gel electrophoresis on 12% Bis/Tris acrylamide gels (Bio-Rad, Sydney, Australia). Proteins were transferred onto nitrocellulose, and blocked. Membranes were incubated with a primary antibody for human HLA-DP/ DQ/DR (1: 200 Dako, Campbellfield, Victoria, Australia; M0775, clone CR3/ 43) or b-actin (1: 10 000 Chemicon, Sydney, Australia; MAB1501) at 4 1C overnight. Membranes were washed, and incubated with anti-mouse peroxidase-conjugated affinity-purified secondary antibodies (1: 1000 in blocking solution, Chemicon) at room temperature for 1 h. After further washing, bound antibodies were incubated with enhanced chemilumines- Increased inflammatory markers in schizophrenia SG Fillman et al cence reagent (Millipore, Sydney, Australia), and visualized on a Chemidoc Imaging System (Bio-Rad). The expected B30-kDa band was quantitated by densitometry using ImageJ (Version 1.4, rsbweb.nih.gov/ij/, U.S. National Institute of Health, Bethesda, MD, USA). Each gel was normalized to an internal control and b-actin expression, which did not differ between diagnostic conditions. The experiment was performed twice and data averaged.
Immunohistochemistry 3,3 0 -Diaminobenzidine immunohistochemistry was performed as previously described. 33 Fresh frozen tissue sections were thawed and fixed in 4% paraformaldehyde and then treated for peroxidase activity. Anti-HLA-DP/DR/DQ primary antibody (1: 1000, Dako; M0775) was applied overnight at 4 1C, followed by washes and incubation with horse antimouse IgG biotinylated secondary antibody (1: 1000, Vector Laboratories, Burlingame, CA, USA). Slides were washed and incubated with avidin--biotin--peroxidase complex (Vectastain ABC kit; Vector Laboratories), treated with 3,3 0 -Diaminobenzidine (Sigma, Castle Hill, NSW, Australia), washed, stained with Nissl and coverslipped.
Immunohistochemistry analysis
Images for analysis were obtained on a Nikon Eclipse 80i microscope (Coherent Scientific, Hilton, SA, Australia) with a Â 10 lens, numerical aperture (NA) 0.17 and stitched together using Stereoinvestigator software. Layers 3, 5/6 and white matter were identified and marked on each image. Five boxes of 0.3 mm 2 were placed randomly 200--400 mm apart within each layer. HLA-DP/DR/DQ stained cells were counted (blind to diagnosis) within the boxes with 2 permissive and 2 non permissive edges, using ImageJ. Immuno-positive cells were defined as darkly 3,3 0 -diaminobenzidine stained, with filamentous extensions and a Nissl nuclear-stained core.
Statistical analysis
Statistical tests of qPCR data were performed using SPSS statistics (version 19, OSX, IBM, Armonk, NY, USA). A Grubbs test was used to identify population outliers in qPCR, immunohistochemistry, and western blotting (all outliers had high expression values, on average: n ¼ 1.57, range: 0--5 individuals per measurement per diagnostic group were dropped). Further qPCR statistical analysis was performed as detailed in Weickert et al. 28 Owing to their initial nonnormal distributions, NFKB1, SERPINA3, IL-8, IL-6, IL6ST, IL-1b and PTGS2 mRNA levels were log 10 transformed with HLA-DP/DR/DQ western blotting data being square root transformed. Pearson's correlations were performed between the immunohistochemical cell density of cortical layers in an individual. Stepwise regressions using demographic variables (age, pH, PMI, RIN) were used to identify covariates for analysis of covariance (ANCOVA) of experimentally measured mRNA values. Significantly identified demographic variables are indicated in the individual experimental results. Relationships between inflammatory mRNAs and HLA-DP/DR/DQ density were examined using stepwise regression and the transformed, normally distributed, variables with missing values were replaced by standard means to enable retention of the greatest number of individuals. The existence of an inflammatory subgroup was tested using a recursive twostep cluster analysis on the entire case--control cohort with missing values replaced by means. 34 The overall model quality was required to be 40.5, with predictors removed if they did not contribute 40.5 to the model on a scale of 0--1.0. Characteristics of this subgroup were identified by using t-tests for normally distributed continuous variables and w 2 tests for categorical. Individuals from this category were further examined for correlations with brain-derived neurotrophic factor (BDNF) and interneuron marker mRNA expression using previously reported data. 35, 36 Spearman's correlation tests were performed on clinical variables of duration of disease and chlorpromazine dosages.
RESULTS
The inflammatory pathway is upregulated in schizophrenia Processing of the NGS read counts in EdgeR yielded a total of 798 differentially regulated transcripts in schizophrenia DLPFC as compared with controls (FDRo0.05) (Supplementary Table 2 ). These transcripts were converted to genes using Ingenuity, yielding 316 genes, whose mRNA expression met the criteria for inclusion into our network analysis. Of these, 115 were core genes used to seed the network analysis. Ingenuity identified five custom networks and five biological functions (not mutually exclusive) that were significantly differentially regulated in our sample (Supplementary Table 3 ). The category of inflammatory response reoccurred in these lists. We created a custom pathway into which we inserted the seven most changed and most commonly listed inflammatory genes ( Figure 1) . We confirmed the changes detected by NGS by using qPCR in an expanded cohort . Two inflammatory related transcripts suggested by Ingenuity, but not differentially regulated in the NGS data; IL6ST (IL-6 signal transducer also known as GP130) and NFKB1, were also not found to be significantly changed between our diagnostic groups by qPCR.
Increased microglial markers in schizophrenia The HLA-DP/DR/DQ genes encode subunits of the MHC-II receptor expressed on antigen-presenting cells, including microglia. Western blotting using an antibody specific for the b subunit common to the DP/DR/DQ subtypes showed a number of bands, but only one at the predicted 27--30 kD range. The intensity of this band was highly varied between individuals but showed a significant increase in schizophrenia (t(67) ¼ 3.131, P ¼ 0.002) (Figures 3a and b) . Additionally, we found an increase in 8/10 microglial mRNA markers which were reliably measured by NGS and significantly differentially expressed between individuals with schizophrenia and controls (Supplementary (Figures 3c--e) . There were fewer immuno-positive cells to be counted in the gray matter compared with the white matter, and no significant changes were detectable in either layer III or V/VI (mean cells mm À2 gray matter, SCZ: 50.36, CON: 48.98). However, we found that microglia densities in both layers were significantly correlated with white matter cell densities. (all cases: layer 3: r ¼ 0.546, Po0.0001, layer 5/6: r ¼ 0.627, Po0.0001). A subgroup of individuals with schizophrenia have elevated inflammatory markers Two-step cluster analysis on the entire cohort revealed 18 individuals who represented a high inflammatory factor group (Figure 4a ). The individuals in this cluster were defined by high IL-1b, IL-6, IL-8 and SERPINA3 mRNA expression (all t44.7, all Po0.001). This group was primarily composed of individuals with schizophrenia as opposed to controls (n ¼ 14 vs 4, w 2 ¼ 7.341, P ¼ 0.007). The high-inflammation group did not include any of the seven individuals with schizoaffective disorder (w 2 ¼ 5.255, P ¼ 0.02), any individuals with the DSM-IV-defined depressive subtype of schizophrenia (w 2 ¼ 4.359, P ¼ 0.037) and had fewer individuals with recorded suicide attempts (w 2 ¼ 5.451, P ¼ 0.02). Other characteristics of this group include high mRNA expression of IL6ST (IL6ST t(70) ¼ 2.174, P ¼ 0.033). Also, when comparing this high-inflammatory group to the low-inflammatory group (including both schizophrenia and controls), using previously published inhibitory interneuron marker and BDNF changes in our cohort, we find lower somatostatin (SST), parvalbumin, neuropeptide Y, glutamate decarboxylase 67 and BDNF I-IX and IV-IX transcripts (SST: t(69) ¼ À4.370, Po0.001, PV: t(66) ¼ À2.802, P ¼ 0.007, NPY: . In order to interpret how this inflammatory clustering interacts with the diagnosis of schizophrenia, we have compared the high-and low-inflammatory clusters in schizophrenia using previous measurements (Figures 4b  and c) . The mRNA expression in the high-inflammatory group with schizophrenia was significantly greater than the low-inflammatory group for IL-6, SERPINA3, IL-1b and IL-8 (IL-6: t(33) ¼ 6.676, Po0.001, SERPINA3: t(29) ¼ 4.258, Po0.001, IL-1b: t(31) ¼ 4.476, Po0.001, IL-8: t(28) ¼ 3.149, P ¼ 0.004), with IL6ST showing a nonsignificant trend (t(34) ¼ 1.958, P ¼ 0.058). When examining BDNF, the high-inflammatory group with schizophrenia shows a decrease in mRNA levels compared with the low-inflammatory group (BDNF transcripts I-IX and IV-IX: t(35) ¼ À2.720, P ¼ 0.01 and t(35) ¼ À3.840, Po0.001, respectively). Interneuron markers remained below control levels for both high-and low-inflammatory groups, but this deficit was significantly exaggerated for somatostatin (t(33) ¼ À3.658, P ¼ 0.001), and showed a similar trend in parvalbumin and GAD 67 Table 5) .
IL-1b is linked to MHC-II-expressing cells in the white matter
A review of the clinical records showed that 28 individuals (13 controls and 15 individuals with schizophrenia) had evidence of body inflammation in the last week leading up to their death. Those with schizophrenia displayed forms of chronic airway disease (n ¼ 10), flu-like symptoms (n ¼ 2), sepsis (n ¼ 2) and pancreatitis. Controls displayed a wider variety of conditions, including flu-like symptoms (n ¼ 3), recent onset cough (n ¼ 3), cancer (n ¼ 2), respiratory failure (n ¼ 2) and a variety of maladies (peritonitis, cyst and asthma) in individuals. Of those in the high-inflammatory cluster, 64% of individuals with the diagnosis of schizophrenia (n ¼ 9/14), as compared to 25% of the controls (n ¼ 1/4), had shown an evidence of recent peripheral inflammation. In the low-inflammatory cluster, 74% (n ¼ 17/23) of individuals with schizophrenia and 87% (n ¼ 21/33) of controls showed no evidence of recent body inflammation. This distribution showed a trend toward a biased distribution in the entire cohort (w 2 ¼ 3.175, P ¼ 0.075), as well as a significant nonrandom distribution of schizophrenia cases with evidence of body inflammation within a week of death and high neuroinflammatory markers in the brain (w 2 ¼ 5.268, P ¼ 0.02). However, similar statistics were not performed for controls because of low counts in the high-inflammatory group. 
DISCUSSION
We have identified that genes involved in inflammation, specifically interleukins (ILs), have increased expression in the DLPFC of individuals with schizophrenia. This is the first study to show increased cortical cytokine mRNA expression in people with schizophrenia, confirming the greater sensitivity of NGS over previous microarray studies. Concurrently, we have observed an increase in the density of microglia/antigen-presenting cells that express MHC-II receptors in the white matter in schizophrenia. There is a strong positive relationship, demonstrated through regression, between these microglia density and IL-1b mRNA expression, which is especially evident in individuals affected by schizophrenia.
Postmortem experiments yield a snapshot of the disease process, and therefore it is difficult to establish if these inflammatory changes are a cause, consequence, confound or compensation of the disease. 37 There is a substantial amount of evidence from epidemiological studies, animal modeling and direct serum cytokine measurements pointing to inflammatory changes as being causal. Environmental influences such as maternal infection, obstetric complications and early-life stress have been shown to lead to greater risk of schizophrenia and elevated cytokine levels. Maternal infection, in particular, has been demonstrated in animal models using both Poly: IC (inducing an antiviral response) and lipopolysaccharide (inducing an antibacterial response) to result in behavioral phenotypes and altered biochemistry similar to schizophrenia. 38--40 These immunological responses can also be exacerbated by chronic mild stress, which in rodents and humans increases the cortical/ peripheral expression of IL-1b, TNF-a and IL-6, as is found in our schizophrenia cohort. 41--43 Finally, direct measurement of blood/ CSF cytokine levels of individuals who are at high risk, as well as those who are acutely psychotic and medication naive, have shown elevations in IL-1b and IL-6. 12,16,17,19,21,44--46 The evidence from these three lines of research all point to inflammatory dysregulation being a causal event in the disease course. In our cohort, those patients with the shortest duration of disease (average: 19 years) had the greatest inflammatory mRNA changes matching this proposal. In fact, antipsychotics are thought to decrease the levels of inflammatory cytokines relative to the initial untreated status. 9, 12 As our finding of increased immune activation is statistically, if not directly, linked to decreased health Only four controls, 10% of the total number of controls and 5% of the whole cohort, are included in this cluster (dark red). Fourteen of these 18 individuals have schizophrenia, representing 38% of individuals with schizophrenia/schizoaffective disorder and 19% of the whole cohort (dark blue). The remaining 23 individuals (61%) with schizophrenia/schizoaffective disorder represent 31% of the whole cohort. The individuals with schizophrenia can be divided into high-inflammatory (dark blue) and low-inflammatory (light blue) categories. When mRNA expression of inflammation-related genes is normalized to controls, significant differential expression between individuals with schizophrenia in the high and low inflammatory groups can been seen in the four genes that define the clusters (b, green square). Looking at these same groups using previously published data shows significant differences in both brain-derived neurotrophic factor (BDNF) transcripts and somatostatin (c). Note that all interneuron markers, but not BDNF transcripts, have exaggerated decreases in the high-inflammatory group (t test, T Po0.1, *Po0.05, **Po0.01).
and viability of interneurons (specifically somatostatin positive), our results suggest that an increased neuroimmune response is linked to interneuron distress, with further studies needed to confirm the temporal pathological order. 47--49 Microglia, responsible for much of the cortex's cytokine production, have also been shown to be essential for learning and memory in the hippocampus. 50, 51 Much of this is done through modulation of IL-1b expression with increased levels being detrimental to spatial and working memory when administered intracerebroventrally or genetically overexpressed.
52--54 As we find increased microglial staining and IL-1b mRNA expression in (a subset of cases with) schizophrenia, this could indicate a possible mechanism for the cognitive deficits observed in patients. Examining the number and density of microglia cells in schizophrenia has been done using a number of different markers with varying results. 55--60 In our study, the antibody binds to a common epitope on the b-subunit of the MHC-II receptor capturing the combined proteins of HLA-DP/DQ/ DR. The MHC-II receptor is constitutively expressed by microglia and other antigen-presenting cells, but is upregulated in response to stress/activation. 51 Four out of five postmortem studies examining HLA-DP/DQ/DR or HLA-DR specifically found quantitative or qualitative increases in schizophrenia. 55--59 Two in vivo PET and one in vitro binding study used [
11 C]PK11195 as a ligand for the translocater protein (formerly peripheral-type benzodiazepine receptor), a marker for microglia, and found increased gray matter and hippocampus binding, although an in vitro study found decreases in superior parietal cortex, primary visual cortex and putamen. 25--27 It is also notable that only Doorduin et al.
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reported on white matter and observed a 20%, nonsignificant increase. The small number of subjects in these PET studies (n ¼ 16--32) suggests that cohort size may result in these inconsistent findings, especially when taken in context of the heterogeneity present in our (n ¼ 74) cohort. Our study is the first to establish mRNA changes in inflammatory cytokines in the DLPFC of individuals with schizophrenia. The greater sensitivity of NGS has allowed us to form an important link between previously observed peripheral immune-related changes and those in the cortex. Elevated IL-1b expression is known to cause increased secretion of IL-6 from microglia, astrocytes and neurons. 61--63 This IL-6 elevation could subsequently lead to problems in cell migration, which may be one reason for the greater density of inhibitory interneurons in the white matter of individuals with schizophrenia. 33, 64 The IL-6 receptor has been shown to exist primarily in neurons, and one study suggests specifically in parvalbumin-positive interneurons, although glial expression has been found as well. 65--69 This fits well with the model proposed by Behrens et al.
47--49 of IL-6-mediated production of reactive oxidative species through the NADPH-oxidase pathway leading to deficits in interneurons. 47 Although our results show elevated IL-6, as well as decreased inhibitory interneuron markers such as somatostatin, we do not find any significant changes in NOX2 (CYBB); the models proposed intermediate enzyme, any of the necessary cofactors (CYBA, NCF1 and NCF2) or a change in the IL6ST, required for IL-6 signal transduction between schizophrenia and controls (data not shown). It is possible, however, that posttranscriptional changes such as protein stability or enzyme activity levels, which we did not measure, are responsible for the increased activity of NOX2 observed previously with high IL-6 expression. 48, 49 Others have observed a negative relationship between IL-6 and BDNF levels in schizophrenia patients, which may explain why the BDNF levels for 5 0 exons I and IV were significantly decreased in the schizophrenia patients who are members of the high-inflammatory cluster compared with those patients in the low-inflammatory cluster. 70 The individuals in the low-inflammatory cluster show higher than control levels of BDNF mRNA (40--50%), which is consistent with our previously observed overall increase in schizophrenia BDNF I-IX expression in our cohort. 36 However, in exon IV-IX, we previously found no diagnostic change but currently observe increased mRNA expression in the lowinflammatory cluster, and a decrease in BDNF mRNA in the high-inflammatory cluster when compared with controls suggesting a great deal of heterogeneity in cortical BDNF mRNA levels that may be related to neuroinflammation. 36 The decrease in BDNF mRNA expression in the high-inflammatory patients may also account for the exacerbated somatostatin mRNA decrease in the group with schizophrenia. 71 In addition to IL-1bs known, modulation of IL-6, IL-1b increases can also result in elevations of IL-8. 72 Indeed, we find significant increases in IL-8 mRNA, and as IL-8 is a potent chemoattractant for a number of immune-related cells including T-cells, neutrophils, basophils and endothelial cells, it is possible that the blood-brain-barrier may be disrupted in schizophrenia. 73 This may explain the observed synergistic increases in brain and blood cytokines of individuals with schizophrenia, and could allow for identification of 'brain events' through the blood. 11, 74, 75 A greater number of individuals with schizophrenia in our cohort display evidence of concurrent peripheral and central inflammatory response than controls, perhaps indicating a predisposition toward increased inflammatory response from a genetic or environmental source. 76, 77 However, a number of individuals with schizophrenia that show no evidence of peripheral body inflammation still display indications of an increased brain inflammatory response and a number of controls with evidence of inflammation in the body do not display elevated levels of brain inflammatory markers. This would suggest that although there may be an interaction between body and brain inflammatory responses, particularly in schizophrenia, it does not appear to co-occur in all cases. As a substantial number of individuals with schizophrenia seem to have an abnormal expression of inflammatory factors, it should be made a priority to identify these individuals and determine which treatments, including prostaglandin synthesis inhibitors and beyond, will be most beneficial. 11, 74, 78 Targeted supplemental intervention of anti-inflammatory agents may be an effective treatment currently available to improve the quality of life of individuals with schizophrenia. 79 
